"This type of prevention can be very useful in controlling infection outbreaks and containing the bird flu pandemic," said an immunologist.

In addition to the ATM Program completion, IPA has now fully satisfied its outstanding obligations with Yorkville Advisors, as Yorkville has converted all principal amounts under the debenture ...

Pursuant to the transaction with Telix, ImaginAb has retained its lead imaging candidate, CD8 ImmunoPET, which is currently in Phase 2 clinical trials and has been licensed by numerous pharmaceutical ...

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the ...

Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the “IPA Family”). Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...

Exclusive global license outside of Greater Chinafor MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) ...

OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...

“Although individual vaccines have been developed and approved for use in humans against SARS-CoV-2 and influenza viruses, there is no vaccine approved to simultaneously protect against both viral ...

A new technology developed at MIT enables scientists to label proteins across millions of individual cells in fully intact 3D ...